Across TCGA pan-cancer cohorts, LINC00293 RNA differs between tumor and matched normal tissue in 1 of 18 cancer types tested, making tumor–normal expression one of LINC00293’s most consistent transcriptional readouts.
The strongest signal is observed in lung adenocarcinoma (LUAD), where LINC00293 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types LINC00293 is over-expressed in tumor.
LUAD are the cancer types where LINC00293 tumor–normal differential expression is most reproducible.